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Economic evaluations conducted alongside randomised controlled trials are a popular vehicle 
for generating high-quality evidence on the incremental cost-effectiveness of competing 
healthcare interventions. Typically, in these studies, resource use (and by extension, 
economic costs) and clinical (or preference-based health) outcomes data are collected 
prospectively for trial participants to estimate the joint distribution of incremental costs and 
incremental benefits associated with the intervention. In this paper, we extend the generalised 
linear mixed-model framework to enable simultaneous modelling of multiple outcomes of 
mixed data types, such as those typically encountered in trial-based economic evaluations, 
taking into account correlation of outcomes due to repeated measurements on the same 
individual and other clustering effects. We provide new wrapper functions to estimate the 
models in Stata and R by maximum and restricted maximum quasi-likelihood and compare 
the performance of the new routines with alternative implementations across a range of 
statistical programming packages. Empirical applications using observed and simulated data 
from clinical trials suggest the new methods produce broadly similar results compared with 
Stata’s merlin and gsem commands and a Bayesian implementation in WinBUGS. We highlight 
that, although these empirical applications primarily focus on trial-based economic 
evaluations, the new methods presented can be generalised to other health economic 
investigations characterised by multivariate hierarchical data structures.  
3 
Introduction 
Economic evaluations conducted alongside randomised controlled trials are a popular vehicle 
for generating high-quality evidence on the incremental cost-effectiveness of competing 
health interventions. Typically, in these studies, resource use (and by extension, economic 
costs) and clinical or preference-based health outcomes data are collected prospectively for 
trial participants to estimate the joint distribution of incremental costs and incremental 
benefits associated with the intervention, taking into account fixed and random sources of 
variation [1, 2]. The term ‘fixed and random source of variation’, as used in this paper, refers 
to the set of explanatory variable(s) whose effect on the response is either assumed to be 
constant (fixed source of variance) or to vary randomly (random source of variance) across 
different realisations of the explanatory variable [3]. Both sources of variance are commonly 
encountered in clinical trial generated cost-effectiveness data. The former because of 
differences in patient characteristics, and the latter as a consequence of study design, such as 
decisions to randomly allocate patients in clusters rather than individually (as in cluster-
randomised trials), recruit across multiple locations (as in multicentre and multinational 
trials) or to measure outcomes at multiple time points during follow-up (repeated measures). 
 
Joint modelling of treatment costs and benefits, in cost-effectiveness analyses based on data 
from clinical trials, is often motivated by a desire to properly characterise uncertainty around 
estimates of incremental cost-effectiveness and display results graphically as cost-
effectiveness planes and cost-effectiveness acceptability curves. If the outcomes are 
sufficiently correlated, there may be additional benefit from being able to borrow information 
across outcomes and estimate variance components and standard errors around parameter 
values more efficiently than in separate univariate analyses [4]. However, joint modelling of 
multiple outcomes is a complicated statistical task if the data are not normally distributed and 
the outcomes are of different data types such that a single probability distribution cannot 
wholly characterise their joint distribution [5, 6]. In such situations, the simplest and most 
straightforward approach is to model outcomes separately assuming appropriate distributional 
forms for each data type, but allow the underlying parameters to be correlated or related in 
some way. This approach requires flexible software for implementation, something that has 
not been readily available in general-purpose statistical programming packages, such as Stata 
and R, familiar to many analysts working on trial-based economic evaluations. As an 
example, the methodology for analysing economic data from clinical trials of the type 
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described above has received substantial attention in the literature - published methodological 
papers include bivariate regressions for economic evaluations based on multicentre and 
multinational clinical trials (see references   [7-9] and the citations therein), cluster-
randomised trials [10-12] and methods for modelling hierarchical cost data [13-15], including 
extensions to allow for modelling healthcare costs and cost-effectiveness in the presence of 
structural zeros [14, 15].  In all but the most straightforward situations where it is reasonable 
to assume normality of outcomes [16], implementation of the methods outlined in these 
papers requires modelling on the net benefit scale [17] or familiarity with specialised 
Bayesian and multi-level modelling software packages, such as WinBUGS [18], JAGS [19], 
MLwiN [20] or the SAS GLIMMIX procedure [6]. An alternative approach that can be 
implemented in most statistical packages is the bootstrap [1, 21]. It has the advantage of 
avoiding parametric assumptions about the data; however, it is computationally intensive, 
especially for complex analytic and missing data problems, as it requires repeated resampling 
of the data many times to accurately approximate the empirical distribution of the parameters 
of interest [1, 21]. 
 
Recently, two new functions have become available (Stata gsem [22] and merlin [23-25] in both 
Stata and R) that allow increasingly complex analysis to be conducted, including modelling 
multiple outcomes of mixed data types and their extensions to longitudinal and time-to-event 
outcomes [24, 25]. The new functions use more accurate numerical integration techniques 
such as the adaptive Gaussian-Hermite quadrature to approximate the model and estimate 
parameters by maximum likelihood. However, maximum likelihood is known to 
underestimate variance components in mixed-effects models, as well as standard errors of 
parameter values more generally in small to moderate sample size applications (i.e. the data 
for analysis is small in relation to the number of parameters to be estimated) [26, 27]. The 
bias in the maximum likelihood estimate of variance components can often be corrected by 
restricted maximum likelihood [26, 27], but this can be difficult to implement via methods 
that approximate the likelihood for the data numerically. 
 
In this paper, we extend the generalised linear mixed-model framework to enable 
simultaneous modelling of multiple outcomes of mixed data types based on pseudo or quasi-
likelihood methods previously proposed by Breslow and Clayton [28],  Wolfinger and 
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OConnell [29] and Lindstrom and Bates for non-linear mixed-effects estimation [30]. These 
methods have been implemented in the SAS GLIMMIX procedure for univariate and multivariate 
cases, R using nmle for non-linear mixed-effects [31] and also in R using glmmPQL for the 
univariate case [32]. The new models may be viewed as multivariate extensions of the 
standard linear and generalised linear mixed-model that has been proposed and refined over 
the past three to four decades [28-30, 33-38]. The proposed models are easy to implement 
and permit maximum likelihood and restricted maximum likelihood estimation. However, 
they may generate less accurate parameter estimates in comparison to methods based on 
numerical integration for certain data types such as binary data when the sample size is small 
[28, 29]. We compare the performance of the new routines with alternative implementations 
across a range of statistical programming packages such as gsem and merlin in Stata, the SAS 
GLIMMIX procedure and Markov Chain Monte Carlo (MCMC) simulation in WinBUGS with 
minimally informative prior distributions placed on all parameters of the model. 
The remainder of the paper is structured as follows. The next section outlines the statistical 
methods for mixed-effects modelling of multiple outcomes of mixed data types and the 
functions to estimate the model. This is followed by a simulation to compare the performance 
of the new routines in terms of estimation bias, root mean square error and confidence 
interval coverage. We also illustrate applications of the methods using observed and 
simulated economic data from clinical trials. The paper ends with concluding remarks and 
pointers for future research. 
 
Methods 
This section outlines the statistical model for analysing multiple outcomes of mixed data 
types such as those typically encountered in trial-based economic evaluations of 
interventions. We consider models with a single grouping factor or random-effect such as 
study-centre, cluster or country and note that extensions to multiple levels of nesting are 
relatively straightforward. Additionally, for ease of notation, we assume the dataset available 
for analysis is balanced with an equal number of observations for all individuals included in 
the analysis and again note that the same modelling logic applies to unbalanced datasets with 
partially observed information on some individuals. 
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A multivariate generalised linear mixed-effects model 
We consider a generalised linear mixed-model of the form 
( )1ijk k ijk ijky g e−= +                                                                                          (1) 
where 
ijky  denotes the kth observation on the jth patient in the ith cluster, ( ).kg  is a 
differentiable monotonic link function of the expectation  ( )ijk ijkE y =  with ( )
1 .kg
−  denoting the 
inverse of ( ).kg  and ijk  is an unobserved or latent variable modelled on the link scale such 
that ( )k ijk ijkg  = .  Examples of the form that ( ).kg  can take include the identity link function for 
a normally distributed response, the logit and probit functions for a binary response and the 
logarithmic function for a gamma or poisson distributed response.  Following Hadfield [39], 
we assume that there exists a probability density function ( ).kf  in the exponential family such 
that ( )( )1|k ijk ijk k ijkf y g −=  denotes the probability of predicting ijky  with error ijke  from 
T T
ijk ijk k ijk ik = +x β z b                         (2) 
where ijkx  and ijkz   with the superscript T  denoting a matrix transpose are known ( 1)kp   
and ( 1)kq   design matrices for fixed and random-effect covariates associated with 
observation ijky , kβ is a vector of unknown population fixed-effect parameters for the kth 
observation of length 
kp  and ikb  is the associated kq dimensional vector of random effects in 
cluster  i. The residual error term ijke  captures any remaining variance in the response not 
accounted for by the fixed and random covariates included in equation (2). For densities in 
the exponential family, this variance can be expressed in the form 
( ) ( )Var |ijk ik k ijk k ijky a  =b  [28, 40] where ( ).k  is specified variance function, ijka  is a 
known constant and k is dispersion parameter associated with the kth measure. Suppressing 
the dependence of quantities on the subscripts j and k identifying individuals and outcome 
measures to aid clarity, equations (1) and (2) may be combined for all observations in the ith 
cluster to form 
( )1i i i i i
−= + +y g X β Zb e        1,2, ,i M=                     (3) 
where 
iy  is a vector of multivariate responses (stacked on top of one another) of length in , ie  
is the corresponding vector of stacked residual errors, ( ).g  is a collection of link functions 
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applied such that a different form is  assumed for the different data types in 
iy  and M  is the 
total number of clusters, repeated measurements, study sites or locations. The design matrices 
iX  and iZ  of dimensions ( )ip n  and ( )iq n , are block-diagonal with each block carrying 
covariate information specific to each measure, β  is a p -dimensional vector of fixed effect 
parameters to be estimated, and 
ib  is the q -dimensional vector of random-effects across all 
measures. Because the dataset is balanced (i.e. every study participant is assumed to have 
data points for all measures of interest) and 
ib is a single-level random-effect, in  is simply the 
total number of outcome measures multiplied by the number of individuals in cluster i.     
 
Following standard formulation of mixed-effects models, we assume that 
ib  is uncorrelated 
with β  and distributed multivariate normal with mean ( )|iE =b β 0   and covariance ( )|iCov =b β G
, where G  is a positive-definite matrix (of dimension equal to the number of random-effect 
terms in the model) whose diagonal and off-diagonal entries carry respectively between-
cluster variance and covariance terms to be estimated from the data. Similarly, we assume 
that the residual error vector 
ie  with mean ( )|i iE =e b 0  and covariance ( )|i i iCov =e b R  is 
uncorrelated with β  and 
ib , where iR  is a ( )i in n  variance-covariance matrix for the residual 
errors in cluster i. To complete the specification, this residual variance-covariance matrix is 
decomposed into a product of simpler matrices of standard deviations and correlations [29, 
37] 
1/ 2 1/ 2
i i i i=R V C V            1,2, ,i M=                      (4) 
where iV  is a diagonal matrix of known variance functions evaluated at iμ  and iC  is a 
known positive definite matrix of correlations for the within-cluster errors ie .  Usually, both 
iV and iC  are large square matrices of dimension ( )i in n  parameterised using fewer variance 
and correlation terms to make them identifiable [37]. 
 
It is common in the parameterization of mixed-effects models, to assume that observations 
from the same cluster are conditionally independent given the random effects in univariate 
and multivariate models and across outcome measures in the multivariate setting (see 
Gueorguieva and Agresti [41], Gueorguieva [42] and Crowther [24]). This assumption is 
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equivalent to setting the off-diagonals of iC  to zero. Thus, the above specification explicitly 
allows for the conditional independence assumption to be relaxed through formulating a 
correlation structure for the within-cluster errors similar to the population-average approach 
of generalised estimating equations [43]. 
 
Quasi-likelihood estimation 
The model specified above reduces a multidimensional problem to a unidimensional one by 
stacking outcome measures to form a univariate response followed by appropriate 
parameterization of fixed and random-effects, and the variance components. Maximum 
likelihood estimation of the univariate model has been studied extensively [6, 28, 30, 37]  and 
requires evaluating a (potentially) high dimensional integral of the form 
( ) ( | ) ( )i i i i ip p p d= y y b b b        1,2, ,i M=            (5) 
where ( )ip y  is the marginal density of iy ,  ( | )i ip y b is the conditional density of  iy  given 
the random effects  ib  and ( )ip b  is prior density for  ib . This integral does not generally 
have a closed-form solution because the expectation i i i+X β Z b  defined in equation (2) is 
non-linear in the random effects for non-normally distributed response modelled on a non-
identity link scale [28, 30, 37]. Instead, estimation usually proceeds via approximate methods 
such as linearization or numerical integration. Numerical integration techniques provide a 
more accurate approximation of the integral than methods based on linearization, but are 
computationally intensive and only allow maximum likelihood estimation which is known to 
underestimate variance and covariance terms in small sample situations [26, 27]. 
Linearization methods can be less accurate than numerical integration for certain data types 
such as binary responses. However, they are easy to implement and maximum likelihood and 
restricted maximum likelihood estimation are possible. The restricted maximum likelihood 
criterion is desirable as a method for unbiased estimation of variance parameters when the 
sample size is small relative to the number of parameters to be estimated [26, 27]. 
 
Linearization based methods have been implemented in mixed-effects packages such as 
glmmPQL from the R package MASS  [32], nlme from the R package of the same name that fits 
non-linear mixed-effects models to normally distributed response [44], the menl command for 
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non-linear mixed-effects in Stata [45] and the SAS GLIMMIX procedure [46]. In Appendix A, we 
show how these methods can be used to estimate the model specified in equations (1) to (4) 
by penalised quasi-likelihood [28-30] based on a two-step algorithm. In the first step, a 
linearized response is generated separately for each data type as a first-order Taylor series 
approximation to the response variable on the link scale. The stacked vector of linearized 
responses is then jointly estimated in the second step. The algorithm involves iterating 
between these two steps until convergence. Because outcome measures are modelled jointly 
on the scale of the link functions, the model can be fitted in any statistical software package 
that permits mixed-effects modelling of a normally distributed response with heteroscedastic 
error structures to enable the variance of the stacked vector of responses to vary across 
outcomes. 
 
We provide wrapper functions to implement these routines by maximum likelihood and 
restricted maximum likelihood in Stata and R, which themselves call the functions mixed and 
lme, respectively (see appendix B). The implementation in R can fit models that satisfy the 
conditional independence assumption as well as make use of the extensive library of variance 
and correlation structures available in the nlme package to fit models that relax this assumption 
based on the decomposition in equation (4). In contrast, only models that assume conditional 
independence given the random-effects are possible with the Stata implementation because 
the mixed command does not appear have an equivalent library of correlation structures and 
functions available in the nlme package. We compare the performance of these routines with 
the SAS GLIMMIX procedure and the new Stata commands merlin and gsem for fitting multivariate 
linear and generalised linear and non-linear mixed-effects models. Table 1 summarises the 
type of distribution and link functions currently available within each package. The Stata 
command merlin (and an R package of the same name [25]) offers additional functionality in 
allowing users to define any distribution of interest, thus providing flexibility to model 





We simulated data to represent a two-arm cluster-randomised controlled trial that recruited a 
relatively small sample of 200 patients across 10 clusters (study-site or country in the case of 
a multicentre or multinational trial, respectively). In the simulation, we consider a bivariate 
response ( )1 2,
T
ij ij ijY y y= with observation 1ijy  and 2ijy denoting measurements of total costs 
and effects, for patient j in cluster i generated from: 
( )~ Gamma ,ijk ik kY    
( ) 0 1log ijk k k ij ikt b  = +  + ,  1,2, ,i n=   1,2, , ij n=  1, 2k =           (6) 
where ( )E ijk ikY =  is the mean effect observed in the ith cluster of size in  with variance
( ) 2 2Var
ikijk w k ik
Y   = =  and dispersion k  specific to outcome k (k=1 for costs and 2 for 
effects). In a cluster randomised trial, patients in the same cluster receive the same treatment 
so that 
ijt  is an indicator variable that equals 1 if cluster  i receives the new treatment and 0 
otherwise. The random-effects ikb  are assumed to be drawn from a bivariate normal 
distribution with mean zero, between-cluster standard variance 2bk  on the log-scale and 
between-cluster correlation b : 
2
1 1 1 2
2
2 1 2 2
~ Normal ,
i b b b b
i b b b b
b
b
   
   
   
=     
    
0 G   1,2, ,i M=  
where M is the total number of clusters. 
In the simulation, we compared the performance of parameter estimation by maximum 
likelihood and restricted maximum likelihood via penalised quasi-likelihood in terms of the 
mean bias, confidence interval coverage and root mean square error. We assume the true net 
benefit is £1,000 in favour of the new treatment if the cost-effectiveness threshold is £20,000 
per unit of effectiveness. Simulated costs and effects from the above model will have a right-
skewed distributional shape appearance with a lower boundary at zero. This is the 
distributional shape that is typical of healthcare costs but is unlike the distributional shape of 
health utilities (from which quality-adjusted life-years (QALYs) can be derived) which 
typically appear left-skewed. Assuming the effectiveness outcome is the QALY, then the 
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simulated effects represent QALYs on a transformed scale such that the corresponding 
QALY value on the natural scale of measurement can be obtained by applying a straight 
forward linear transformation: 
1ij ijQALY rQALY= −   1,2, ,i n=   1,2, , ij n=            (7) 
where rQALYij is the simulated QALY value for patient j in cluster i and QALYij the linear 
transformation of  rQALYij to generate the corresponding QALY value that would be observed 
in practice and left-skewed in distribution. 
 
Simulation parameters and algorithm 
Parameters values used to inform the simulation specified above were taken from the Final 
Case Model of a simulation study by Gomes et al. (2012) [11] in which the authors assessed 
the performance of various statistical methods for cost-effectiveness analysis alongside 
cluster randomised controlled trials. The underlying parameter values in the Gomes et al. 
study were based on a systematic review the authors have undertaken to identify plausible 
estimates of parameter values for economic evaluation alongside cluster-RCTs. Table 1 of 
their paper summarises this data and the justification for each value used in their simulation. 
Because the simulation model in equation (6) is a multiplicative treatment-effect model, each 
parameter value used in the Gomes et al.’s simulation need to be transformed to generate the 
corresponding estimate on the logarithmic-scale.  Table 2 displays Gomes et al.’s data and the 
corresponding log-transformed value generated for the simulation model above. Based on a 
description of their simulation, we set 01 log(£100) = , 11 log(£600) log(£500) = − , 
02 log(0.125) = , 12 log(0.125) log(0.20) = −  representing overall mean incremental costs of 
£500,  incremental mean effects of 0.075 and mean incremental net monetary benefit of 
£1000 at cost-effectiveness threshold of £20,000 per QALY considered by Gomes et al.  
 
To derive the required variance and dispersion terms on the log-scale, we first reconstructed 
Gomes et al.’s data using their additive treatment effects generalised mixed-effects model 
assuming the errors follow a gamma distribution.  From the reconstructed data, we took the 
logarithm of the patient-level costs and effects (QALYs). We used this log-transformed data 
to estimate the between-cluster variance (defined as the variance of the cluster-mean costs 
and cluster mean effects on the log-scale) and the error variance (defined as the mean of the 
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squared within-cluster patient-level errors or deviations). Based on these calculations, we set 
the between-cluster standard deviations on the log-scale 1 0.152b =  and 2 0.121b =  
corresponding to 1 £11.47b =  and 2 0.014b =  on the natural scale of measurement for costs 
and effects respectively. Finally, the degree of skewness of the gamma distributed random 
variable is a function of the dispersion factor which can be derived from the coefficient of 
variation. From the reconstructed data, we estimated the coefficient of variation on the log-
scale to be 0.65 corresponding to a coefficient of variation of 0.5 assumed for both costs and 
QALYs on the natural scale of measurement.  A step by step outline of the simulation 
algorithm is given below: 
 
1. Simulate costs and QALYs for a two-arm cluster- RCT from an additive treatment 
effect generalised mixed-effects model with gamma-distributed error structure based 
on Gomes et al.’s data.  
2. Calculate log (costs) and log (QALYs) for each patient and use this to estimate the 
between-cluster variance 2b  (variance of the cluster-means) and the within-cluster or 
error-variance 2w  on the log-scale.  
3. Estimate the dispersion factor   from the 2w  using the fact that the intra-class 
correlation coefficient (ICC) of a gamma-distributed random variable on the log- 














) where 1  is the trigamma function which 
is the second derivative of the gamma function (Nagakawa et al. 2017 [47]). From the 
above definition of the ICC, it is clear that ( )11   estimates the error variance 2w  on 










 is the 
inverse-trigamma function. 
 
4. Simulate costs and effects data using the simulation model described by equation (6) 
based on the parameter values generated in steps one to three above and fit the 
different models to the data. Obtain the parameter vector and the associated 
covariance matrix from the fitted mixed-effects regression model.  
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5.  Use Monte Carlo simulation to estimate standard errors and confidence intervals for 
the incremental costs, incremental effects, and the incremental net benefit on the 
natural scale of measurement for costs and effectiveness outcomes. This involves 
generating a 1000 replicates of the regression parameters assuming a multivariate 
normal distribution for the parameter estimates on the log-scale. 
 
6. Repeat steps three to five 2000 times, each time calculating cost-effectiveness 
parameters and their associated standard errors and confidence intervals.    
We compared the performance of parameter estimation by maximum likelihood and 
restricted maximum likelihood via penalised quasi-likelihood in terms of the mean bias, 
confidence interval coverage and root mean square error assuming that the true net benefit is 
£1,000 at a cost-effectiveness threshold of £20,000 per QALY or unit of effectiveness. 
Maximum likelihood estimates were obtained by numerical integration via the gsem function 
in Stata and by penalised quasi-likelihood via mixed and lme functions in Stata and R 
respectively. The vce option in Stata was used to obtain robust estimates of the covariance 
matrix of the regression parameters in the maximum likelihood models. Restricted maximum 
likelihood estimates were only available via penalised quasi-likelihood using the mixed and lme 
functions. 
Simulation results 
The simulation results are presented in Table 3 for the base-case parameter values presented 
in Table 2 and three scenarios. The scenarios tested the performance of the methods when (i) 
the total number of clusters is decreased from 10 to 5, (ii) the cluster size is increased from 20 
to 50 individuals and (iii) the coefficient of variation is increased from 0.5 to 1.0 reflecting a 
higher degree of skewness in distribution (Figure 1). For the base case simulation with a 
sample size of 200 individuals recruited across 10 clusters, the mean bias was small in all 
implementations of the two estimation procedures. The restricted maximum likelihood 
estimates (mean bias ranged from £1.11 to £1.31 assuming the true net benefit is £1000) 
were, however, less biased on average than the corresponding estimates obtained by 
maximum likelihood (range in mean bias £3.00 to £5.85) (Table 3). Similarly, all models 
produced 95% confidence interval coverage probabilities greater than 0.90, but the restricted 
maximum likelihood estimates were closer to the desired 0.95 nominal value than the 
corresponding coverage probabilities obtained via maximum likelihood.  
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For a reduced sample size of 100 individuals across 5 clusters (scenario 1) of equal size, the 
estimation bias increased compared with the base-case modelling assumptions, but the impact 
on model performance was more pronounced for confidence interval coverage (Scenario 1, 
Table 2). At this small number of clusters and sample size, maximum likelihood generated 
coverage probabilities that are less than 0.85. In contrast, coverage in the restricted maximum 
likelihood models remained relatively unaffected by the reduction in sample size. Figure 2 
shows the relationship between model performance and sample size by varying the number of 
clusters but keeping the cluster size fixed at 20 individuals. Estimation bias decreased 
towards zero with an increasing number of clusters and the confidence interval coverage 
converged to 0.95. 
 
Increasing the sample size to 500 individuals spread across the 10 clusters by increasing the 
cluster size to 50 (scenario 2) produced less biased estimates of the incremental net benefit 
and better confidence coverage for all models compared with the base-case simulation. 
Maximum likelihood estimation via the gsem command in Stata was the least biased compared 
with maximum likelihood and restricted maximum likelihood estimation by penalised quasi-
likelihood. Figure 3 shows the relationship between sample size and model performance 
when the total number of cluster is fixed at 10. The plot suggests the estimation bias 
decreases as the sample size is increased by increasing the cluster size from 10 to 100 
individuals per cluster, but the confidence interval coverage remains relatively unaffected, 
falling below the desired nominal 0.95 value coverage value for all tested estimation 
procedures.   
 
In the final simulated scenario, the coefficient of variation was increased from 0.5 (base-case 
simulation) to 1.0 (Scenario 3) to reflect greater skewness in the data (Figure 1) for a sample 
size of 200 individuals spread equally across 10 clusters. This increased the bias in the 
estimation of the incremental net benefit by maximum likelihood but decreased the bias in the 
estimates generated by the restricted maximum likelihood models. 
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Application to data from clinical trials 
Example 1: UK FASHION trial 
UK FASHION was a pragmatic two parallel-arm multicentre randomised controlled trial that 
evaluated the clinical and cost-effectiveness of arthroscopy surgery versus physiotherapy as 
treatment options for hip pain resulting from femoroacetabular impingement syndrome [48]. 
The trial recruited a total of 348 patients across 23 hospitals and randomly assigned 171 to 
surgery and 177 to physiotherapy. Participants were followed up for 12 months, and data 
collected prospectively at baseline and at six and twelve months post-randomisation. The 
primary outcome was the hip-related quality of life, measured by the International Hip 
Outcome Tool (iHOT-33) [49], a validated patient-reported hip-related quality of life 
measure for young, active patients with hip disorders.  At each assessment point, participants 
were asked to report this outcome and their health-related quality of life measured by the EQ-
5D-5L and SF-12 version 2, as well as health and social care resource use and costs. The 
clinical outcomes data were analysed based on intention-to-treat principles and took the form 
of a mixed-effects multivariable linear regression that included treatment allocation, 
impingement type, gender and baseline scores for relevant outcomes as fixed covariates and a 
random term for study-site [50]. A prospective within-trial cost-utility analysis was also 
conducted from a UK National Health Service and Personal Social Services (NHS/PSS) 
perspective and a 12-month time horizon [50]. The base case analysis closely mirrored the 
analytic model for the clinical outcomes and took the form of bivariate seemingly unrelated 
regressions using imputed attributable costs and EQ-5D generated QALYs as outcomes and 
treatment allocation, gender, impingement type and baseline scores as fixed-effects. Also, 
study-site was included as a fixed covariate, unlike the clinical outcomes model, which 
included this variable as a random-effect. Including study-site as a fixed effect in the 
economic analysis was done partly for practical reasons and partly because it was not 
expected a priori for the treatment effect to differ markedly across NHS centres. Further 
details of the study design, conduct and findings are available from the published study 
protocol [48] and the main trial paper [50]. 
 
To illustrate the methods outlined in this paper, we restrict ourselves to 263 (132 in the 
surgery group and 131 in the physiotherapy group) of the 348 total trial sample with complete 
outcome and covariate information for the economic analysis [Note: the remaining 85 
participants had missing covariates; hence it was not possible to include these individuals in 
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the regressions]. In this illustration, we assigned a nominal total cost value of £1.00 to two 
patients in the physiotherapy group who had reported a zero cost observation. This was done 
to avoid problems with zero costs when modelling costs using the gamma distribution as the 
two patients did not receive any intervention or report health and social care service use 
during the 12 months of follow-up. 
 
Figure 4 displays the distribution of total costs and QALYs by treatment group during the 12 
month follow-up period. The plots suggest a departure from normality in distribution for both 
outcomes with healthcare costs exhibiting a degree of skewness to the right and QALYs in 
the opposite direction. Residual diagnostic plots obtained from fitting linear mixed-effects 
regressions with covariate adjustment are presented in Figure 5. The normal QQ plots do not 
suggest marked deviations from the normality of the errors, and the scatter plots of the 
residuals versus fitted values suggest the means of the residuals are not too far from zero to 
invalidate the results of a normally distributed error fit. However, the scale-location plots 
suggest the equal variance (homoscedasticity) assumption maybe inappropriate for this data. 
Nevertheless, to illustrate the methods presented here, we fitted three bivariate mixed-effects 
random intercept models with treatment allocation, gender, impingement type, baseline costs 
(cost model) and baseline health-related quality of life scores (QALYs model) as fixed-
effects and study site as a random-effect. In the first two models, a normal distribution with 
identity link function was assumed for QALYs, but costs were modelled using normal and 
gamma distributions with identity and log link functions, respectively. In the third model, the 
distribution of QALYs was converted from left-skew to right skew by applying the 
transformation specified in equation (7).  Costs and the transformed QALY variable were 
then jointly modelled assuming a gamma distribution with log-link function similar to the 
simulation model specified in equation (6).  Note that because equation (7) maps values from 
left to right, individuals with higher QALYs on the untransformed (observed QALY scale) 
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will have lower values on the transformed scale and vice versa. Therefore, parameter 
estimates should be interpreted with care. In particular, estimates of the treatment effect on 
the transformed QALY scale when modelled using gamma regression (equation (6)) should 
be reversed such that the treatment effect favouring active/new treatment on the transformed 
scale should favour the control on the untransformed scale and vice versa.   
 
The results for the FASHION data are presented in Table 4. Estimates of incremental costs 
and incremental QALYs were broadly similar across platforms and estimation procedures. 
The associated standard errors of the incremental costs estimated by different packages were 
also similar across statistical software packages and platforms with maximum likelihood, 
generally producing smaller standard errors than the restricted maximum likelihood and the 
WinBUGS implementations. The model that assumed normally distributed errors for costs 
and QALYs (model F1) generated a mean (standard error) incremental costs ranging from 
£2,573 (£198) to £2609 (£249) and incremental QALYs ranging from -0.012 (0.0184) to -
0.025 (0.026) in the WinBUGS model. Parameter estimates from Model F2 and F3 in which 
the costs were modelled using a gamma distribution with log-link are additive on the log-
scale and multiplicative on the natural scale of measurement. Therefore log-cost and log-
QALY differences generated from the two models were combined with the intercept-term for 
each outcome and back-transformed to generate incremental costs and incremental QALYs 
for surgery compared with physiotherapy on the natural scale of measurement [51]. This 
produced incremental costs ranging from £3,220 (£584) to £3,281 (£567) and incremental 
QALYs ranging from 0.0036 (0.019) to 0.0012 (0.042) in favour of the surgery. 
 
Example 2: GRACE trial 
GRACE was a multinational, randomised placebo-controlled trial that assessed the clinical 
and cost-effectiveness of amoxicillin for acute lower respiratory tract infection in people aged 
60 years or older [52, 53]. Two thousand and sixty patients were recruited from primary care 
practices in 12 European countries (Belgium, England, France, Germany, Italy, the 
Netherlands, Poland, Slovakia, Slovenia, Spain, Sweden, and Wales) and randomised to 
amoxicillin (n=1037) or placebo (n=1023).  Follow-up was 28 days from randomisation. The 
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primary clinical outcome was the duration of symptoms dichotomised to generate a binary 
response reflecting mild to moderate versus severe cough. Cost-effectiveness was assessed 
from the perspective of society with costs expressed in Euros and in 2012 prices. QALYs 
were calculated from EQ-5D-3L data collected at baseline, and weekly over the 28-day 
follow-up period. The trial methods, results, and the subsequent economic evaluation are 
published elsewhere [52, 53]. We use the GRACE data here to illustrate simultaneous 
modelling of three outcomes (costs, QALYs and proportion with a severe cough) each of 
which is of a different data form. These types of analyses can be useful for economic 
evaluations conducted alongside multinational, multicentre or cluster randomised controlled 
trials where the aim is to express cost-effectiveness using alternative measures of benefit or 
effectiveness. For example, cost-effectiveness and cost-utility analyses can be conducted 
simultaneously in a single analytic model. If outcomes are sufficiently correlated, then there 
may be gains in precision from modelling the between-outcome and between-cluster 
correlations. 
 
Figure 6 displays the distribution of total costs and QALYs accrued over the 28-day follow-
up by treatment group. The plots suggest a departure from normality in distribution for both 
outcomes with healthcare costs exhibiting the typical skewness to the right and QALYs in the 
opposite direction. The scale-location plots show evidence of heteroscedasticity, suggesting 
the constant variance assumption implied in a linear mixed-effects model may be 
inappropriate for the GRACE data (Figure 7).  We fitted three trivariate mixed-effects 
random coefficient regressions with treatment allocation, age, gender, and baseline utility as 
fixed-effect covariates and study-country as random-effect. In the first analysis (Model G1), 
we assumed costs and QALYs follow a normal distribution whilst the severity of cough was 
modelled using a binomial distribution. For the second model (Model G2), costs were 
modelled using a gamma distribution with a log link function to accommodate skewness in 
the data whilst the distributions for QALYs and severity of cough remain the same as Model 
G1. The third model assumed that costs and QALYs follow a gamma distribution with the 
transformation implied by equation (7) applied to the QALY variable. 
 
Adjusted estimates of the incremental mean costs, incremental mean QALYs and an 
incremental mean reduction in the proportion with a severe cough for amoxicillin compared 
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with placebo, together with the associated standard errors from fitting these models are 
presented in Table 5. Estimates of incremental costs and incremental QALYs and the 
corresponding standard errors were broadly similar across alternative estimation procedures. 
In this example, the sample size of 2060 patients from 12 countries is large, such that all three 
estimation procedures (maximum likelihood, restricted maximum likelihood and the 
Bayesian MCMC implementation) produced similar estimates of the standard errors 
associated with incremental costs and incremental outcomes. 
 
To illustrate the impact of alternative distributional assumptions on within-trial cost-
effectiveness, we changed the distribution of costs (a normal distribution in model G1 to a 
gamma distribution with log-link in models G2), whilst maintaining the same distributional 
assumptions for QALYs and the probability of severe cough. This has minimal impact on 
incremental QALYs but changed the incremental mean costs from €135.87 (standard error 
€11.22) in model G1 to €107.65 (standard error €14.41) and €107.65 (standard error €14.41). 
For this particular example, the distribution of healthcare costs was skewed to the right, the 
model with gamma-distributed error structure produced a lower estimate of the mean cost 
difference compared with assuming a normal distribution for the costs.   
 
Discussion 
In this paper, we have shown how the generalised linear mixed-model framework may be 
extended to model multiple outcomes of mixed data types typically encountered in many 
health economic investigations. We develop easily implementable tools to estimate the 
models in the statistical programming packages Stata and R and illustrated their applications 
using observed and simulated data from clinical trials. These models may be usefully 
employed, for example, as part of sensitivity analyses to assess the robustness of 
multinational and cluster randomised trial-based cost-effectiveness analyses for departures 
from assumed normality of the error structure. The new tools will also make it possible to 
implement methods in Stata and R for cost-effectiveness analyses that use data from 
multinational trials (previously proposed and implemented in WinBUGS and MLwiN [13, 
14, 17, 54-56]) for normally and non-normally distributed data. Thus, the proposed methods 
can be employed to assess the generalisability of cost-effectiveness results from multinational 
trials where concerns about between-country heterogeneity in healthcare resource use, costs 
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and preference-based health outcome measures (see for example [13, 17, 54-56] for a detailed 
discussion of these issues) makes it increasingly unrealistic to pool healthcare costs across 
countries directly. 
 
The new methods permit restricted maximum likelihood estimation of a mixed-effects 
regression with more than one dependent variable via a penalised quasi-likelihood algorithm. 
This may be advantageous in small to moderate sample size applications as demonstrated in 
our simulations, where restricted maximum likelihood was found to produce 95% confidence 
intervals with better coverage probabilities than maximum likelihood estimation. Our 
simulations suggest that in studies with moderate sample sizes of 200 individuals spread 
equally across ten clusters, both maximum likelihood and restricted maximum likelihood 
generated estimates of incremental net benefit with low bias, but only restricted maximum 
likelihood produced 95% confidence intervals with coverage probabilities close to the desired 
0.95 normal value. Estimation bias increased when the sample size was decreased to 100 
individuals spread equally across five clusters, but the confidence interval coverage generated 
via restricted maximum likelihood remained relatively unaffected (scenario 1, Table 3).  
 
Preliminary results from the simulation and applications to the observed clinical trial data 
also suggest the new routines produced broadly similar point estimates of parameter values 
compared with estimates obtained from Stata’s merlin and gsem and the Bayesian 
implementation in WinBUGS. Estimates of variance components and standard errors of 
parameter values were broadly comparable across platforms when the same method of 
estimation was used, and the dataset was relatively large both in terms of the number of 
clusters and number of individuals per cluster. However, as shown in the simulation, for 
small to moderate sample size applications (i.e. 100 to 200 patients recruited across five to 
ten clusters), maximum likelihood can underestimate the variance components (confidence 
intervals and standard errors around parameter values) compared with restricted maximum 
likelihood. Underestimation of variance components will propagate towards underestimation 
of the uncertainty around final economic endpoints of interest and therefore has implications 
for characterising uncertainty in cost-effectiveness analysis. This is important in trial-based 
economic evaluations as clinical trials often recruit from a relatively small number of study 
sites, centres or clusters. 
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The methods outlined in this paper are not novel in that they are based on extensions of 
pseudo and quasi-likelihood linearization methods [28, 29] proposed over two to three 
decades ago. However, the implementation in R and Stata for modelling mixed outcomes and 
applications to the analysis of economic data from clinical trials is a novel and useful addition 
to the tools available for analysts working in clinical trials research. The new routines are 
easy to implement and can estimate variances and standard errors by restricted maximum 
likelihood that are useful being able to generate confidence intervals with desired coverage in 
small sample situations, but unavailable in gllamm, merlin and gsem that implement more 
accurate numerical integration techniques. For more complex problems, these other functions 
may therefore have advantages in being able to estimate the model more accurately.  In the 
meantime, further simulation-based research is required to understand their statistical 
properties and performance under different modelling assumptions such as in applications 
involving clusters of unequal sizes and alternative specification of the error structure and link 
functions. 
 
The parameterizations outlined in the methods section requires data for analysis to be in long 
format with outcome measures stacked on top of one another to form a single response. This 
parameterization ensures that individuals with partially observed outcomes data (such as 
missing costs but not clinical outcomes) can be included in the analysis under the missing at 
random assumption where covariate information is fully observed. Case-wise deletion of 
partially observed outcome data is avoided in this case, and imputation is not required under 
the missing at random assumption similar to the full information maximum likelihood 
approach of structural equations modelling (see for example Mehta and Neale [57] and the 
references therein). Further research should focus on identifying strategies for handling more 
complex missing data problems such as missing covariates and non-ignorable missingness 
problems where explicit modelling of the missingness mechanism may need to take into 
account hierarchical structures within the data. 
 
Finally, cost-effectiveness analysis requires estimates of incremental costs and incremental 
benefits in the natural unit of measurement. Except for modelling on the identity link scale, 
estimates of incremental costs and effects generated on the scale of the link function should 
22 
be transformed back onto the natural scale of measurement for use in cost-effectiveness 
analysis. This can be achieved by taken random draws from the joint distribution of the 
parameter estimates on the scale of the link function and then back transforming the 
simulated output onto the natural scale of measurement. 
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Supplementary information 
Appendix A: Quasi-likelihood estimation algorithm 
Following Wolfinger and O’Connell (1993) [29], we approximate the model specified by 
equations (3) with 
* *
i i i i i= + +y X β Z b e                                                                                  (A1) 
where *iy is a linearized vector of stacked responses approximating iy  on the link scale in 
cluster i and *ie  is a first-order Taylor series approximation to ie  given by 
( ) ( )
1
* 'ˆ ˆ
i i i ig
−
 = −  e y μ μ                                                                                      (A2) 





−  =  w V μ  is the first-
derivative of the Taylor series expansion evaluated at ˆ iμ [29]. We assume 
*
ie  to be 
multivariate normal with mean  ( )* |i iE =e b 0  and covariance ( )* *|i i iCov =e b R  where the 
matrix *iR  is of dimension ( )i in n  and parametrised as in equation (4) so that the conditional 
and marginal distributions of *iy  given the random effects ib  are given by 
( )* *~ Normal ,i i i i i+y X β Z b R                                                                              (A3) 
( )* *~ Normal , Ti i i i i+y X β ZGZ R                                                                     (A4) 
We may view *iR  as an approximation to iR , the conditional variance-covariance matrix of 
the within-cluster residual errors on the linearized scale. Modelling non-normal data requires 
the linearization step described in equations (A1) and (A2) to generate a linearized response 
on the link scale. We have developed a wrapper functions that implements these routines by 
calling the lme function from the package nlme in R and the mixed package in Stata in the 
following steps: 
Step 1: Fit a separate generalised linear model to different response types in y  assuming an 
appropriate distributional form and link function and obtain the linearized response 
* *= +y β e   with prior weights ŵ . 
Step 2: Fit equation (A4) with the multivariate vector of linearized vector as response by 
calling the lme function within nlme package [44] in R or the mixed command in Stata [45]. 
Step 3: Next generate a new vector of stacked responses 
*
newy  from the estimates of   
ˆ
newβ  





−  =  w μ obtained in step 2. The algorithm consists of 




Table 1: Examples of Stata, R and SAS functions that can fit multivariate generalised linear 
mixed-effects models 
  Stata  R  SAS 
Distribution Common link 
functions supported 
mixed1,2 gsem merlin gllamm  lme1 merlin MCMCglmm  glimmix 
Gaussian Identity, log ✓ ✓ ✓ ✓  ✓ ✓ ✓  ✓ 
Gamma Identity   ✓   ✓ ✓   ✓ 
Gamma Log  ✓ ✓ ✓  ✓ ✓   ✓ 
Binomial Logit, probit  ✓ ✓ ✓  ✓ ✓ ✓  ✓ 
Poisson Log  ✓ ✓ ✓  ✓ ✓ ✓  ✓ 
User defined    ✓    ✓    
1Implemented via wrapper function that calls mixed or lme as described in appendix A 
2Wrapper function to fit non-Gaussian models using the Stata mixed command is currently under development 
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Table 2: Parameters used in the simulation 









Total number of clusters  N 30 10 Test performance of methods when 
No of clusters is small 
No of individuals per 
cluster 
in  
50 20 Test performance of methods when 
sample size is small 
Level of imbalance   0.5 0 Set to zero in the present simulation 
to check the impact of sample size 
only on performance of estimation 
procedures. 
ICC for costs  ICCc 0.05  0.5 Used only to reconstruct Final case of 
Gomes et al.  
ICC for outcomes ICCq 0.02 0.02 Used only to reconstruct Final case of 
Gomes et al 
Coefficient of variation 
(CV) for costs 
CVc 0.5 0.65 Coefficient of variation on log-scale, 
based on reconstructed Final Case 
data (Gomes 2012) 
Coefficient of variation 
for outcomes 
CVq  0 0.65 Not reported in Gomes et al as 
outcomes modelled using a Normal 
distribution. We reconstructed their 
data assuming CV of 0.5 
Individual level 
correlation of costs and 
effects 
1w
  -0.2 0 Assumed outcomes are independent 
given the random effects 
Cluster-level correlation 
1b
  0.1 0.1 Justification given in Gomes et al 
2012. 
Mean costs placebo - - £100 Mean treatment and control group 
costs were taken to give a difference 
of £500 assumed in Gomes et al. 
2012 
Mean costs new 
treatment 
- - £600 
Mean effects placebo - - 0.8 Mean effects for the treatment and 
control groups were taken to give a 
difference of 0.025 assumed in 
Gomes et al. 2012 
Mean effects new 
treatment 
- - 0.875 
ICC = intraclass correlation coefficient 
CV = coefficient of variation (Dispersion equal to CV squared) 
 
 
Table 3: Simulation results based on a true net monetary benefit value of £1,000 at cost-
effectiveness threshold of £20,000 per QALY 





Base case simulation (N = 200 from 10 clusters each of size 20, CV 
= 0.5 for costs and effects, ICCcosts = 0.05, ICCeffects = 0.02) 
   
Stata gsem, ml vce robust 5.85 (13.57) 0.93 331.13 
Stata mixed, ml vce robust via pql 3.00 (13.53) 0.93 329.87 
Stata mixed, reml via pql 1.31 (13.49) 0.95 329.09 
R lme, ml via pql 2.78 (13.52) 0.94 329.79 
R lme, reml via pql 1.11 (13.49) 0.96 329.04 
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Scenario 1 (base case with no. of clusters changed from 10 to 5)  
Stata gsem, ml vce robust 6.4 (26.04) 0.82 481.54 
Stata mixed, ml vce robust via pql 3.91 (25.97) 0.81 480.22 
Stata mixed, reml via pql 4.71 (25.9) 0.96 479.11 
R lme, ml via pql 3.94 (25.97) 0.93 480.33 
R lme, reml via pql 4.64 (25.9) 0.96 479.11 
 
Scenario 2 (base case with cluster size changed from 20 to 50) 
   
Stata gsem, ml vce robust 0.43 (10.14) 0.92 265.5 
Stata mixed, ml vce robust via pql -1.26 (10.12) 0.92 265 
Stata mixed, reml via pql -2.14 (10.11) 0.94 264.7 
R lme, ml via pql -1.44 (10.12) 0.91 264.9 
R lme, reml via pql -2.2 (10.11) 0.94 264.7 
 
Scenario 3 (base case with CV changed from 0.5 to 1.0 for both 
costs and effects) 
   
Stata gsem, ml vce robust 13.77 (23.42) 0.93 593.9 
Stata mixed, ml vce robust via pql 4.73 (23.19) 0.93 588.2 
Stata mixed, reml via pql 0.47 (23.09) 0.94 585.9 
R lme, ml via pql 4.42 (23.18) 0.93 588.1 
R lme, reml via pql 0.31 (23.09) 0.94 585.9 
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Table 4: Illustrated example from clinical trials using the UK FASHION trial data 
(random-intercepts model) 
Models Package, function and 
method of estimation 
Difference in mean 




Model F1: bivariate mixed-
effects regression with 
Costs ~ Normal 
QALYs ~ Normal 
 
Stata mixed, ml via PQL 2575 (196) -0.012 (0.0184) 
Stata mixed, reml via PQL 2573 (198) -0.012 (0.0187) 
Stata merlin, ml 2597 (193) -0.0120 (0.018) 
Stata gsem,  ml 2601 (194) -0.013 (0.019) 
R lme, ml via PQL 2600 (194) -0.010 ( 0.019) 
R lme, reml via PQL 2600 (197) -0.010 ( 0.019) 
WinBUGS MCMC 2609 (249) -0.025 (0.026) 
Model F2: bivariate mixed-
effects regression with 
Costs ~ Gamma (link = log) 
QALYs ~ Normal 
 
Stata mixed, ml via PLQ 3192 (357)  -0.011 (0.0799) 
Stata mixed, reml via PQL 3178 (352)  -0.011 (0.0825) 
Stata merlin, ml 3246 (484) -0.013 (0.019) 
Stata gsem,  ml 3246 (483) -0.012 (0.019) 
R lme, ml via PQL 3246 (483) -0.013 (0.019) 
R lme, reml via PQL 3248 (490) -0.013 (0.019) 
WinBUGS MCMC 3220 (584) -0.013 (0.019) 
 
Model F3: bivariate mixed-
effects regression with 
Costs ~ Gamma (link = log) 
1-QALYs ~ Gamma (link = log) 
 
Stata mixed, ml via PQL  3223 (383)   0.00092 (.0072) 
Stata mixed, reml via PQL 3212 (387)  0.00089 (0.0073) 
Stata merlin, ml   
Stata gsem,  ml robust se 3227 (557) 0.0012 (0.042) 
R lme, ml via PQL 3247 (489) 0.0037 (0.019) 
R lme, reml via PQL 3247 (497) 0.0036 (0.019) 
ml = maximum likelihood/maximum quasi-likelihood; reml = restricted maximum likelihood/ restricted maximum quasi-likelihood; 
MCMC = Markov Chain Monte Carlo simulation; SE = standard error 
Empty cells indicate either that the routine is not available or the model did not converge 
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Table 4: Illustrated example from multinational clinical trial with three outcomes using 
GRACE data (random-coefficient model) 
Models Package, function and 









severe cough (SE) 
Model G1: bivariate 
mixed-effects 
regression with 
Costs ~ Normal 
QALYs ~ Normal 
Cough   ~ Binomial 
(link = log) 
Stata mixed, ml    
Stata mixed, reml    
Stata merlin, ml 154.34 (2.70) 0.0003 (0.0310) -0.0202 (0.0138) 
Stata gsem,  ml 154.34 (2.69) 0.0003 (0.0312) -0.0202 (0.0140) 
R lme, ml via PQL 154.34 (2.71) 0.0003 (0.0311) -0.0202 (0.0137) 
R lme, reml via PQL 135.87 (11.22) 0.0003 (0.0312) -0.0202 (0.0137) 
WinBUGS MCMC 131.90 (14.59) 0.0004 (0.0007) -0.0046 (0.0291) 
Model G2: bivariate 
mixed-effects 
regression with 
Costs ~ Gamma 
(link = log) 
QALYs ~ Normal 
Cough   ~ Binomial 
(link = logit) 
 
Stata mixed, ml via PQL    
Stata mixed, reml via PQL    
Stata merlin, ml 108.97 (14.36) 0.0003 (0.0311) -0.0044 (0.0227) 
Stata gsem,  ml 108.96 (14.36) 0.0003 (0.0311) -0.0044 (0.0227) 
R lme, ml via PQL 108.96 (14.36) 0.0003 (0.0311) -0.0044 (0.0227) 
R lme, reml via PQL 107.65 (14.41) 0.0003 (0.0311) -0.0018 (0.0259) 
WinBUGS MCMC 113.00 (13.21) 0.0002 (0.0005) -0.0073 (0.0267) 
Model G3: bivariate 
mixed-effects 
regression with 
Costs ~ Normal 
1-QALYs ~ 
Gamma (link = log) 
Cough   ~ Binomial 
(link = log) 
Stata mixed, ml via PQL    
Stata mixed, reml via PQL    
Stata merlin, ml    
Stata gsem,  ml    
R lme, ml via PQL 108(14)  
 
0.0002 (0.062) -0.004  (0.02278) 
R lme, reml via PQL 108 (14.39)  
 
0.0002 (0.062)  -0.0011 (0.02605) 
WinBUGS MCMC 107 (12.65) -0.0001 
(0.0047) 
-0.009 (0.0282) 
ml = maximum likelihood/maximum quasi-likelihood; reml = restricted maximum likelihood/ restricted maximum quasi-
likelihood; MCMC = Markov Chain Monte Carlo simulation; SE = standard error. 





Figure 1: simulated distribution of costs and QALYs for different coefficient of 








Figure 2: Mean bias and 95% confidence interval (CI) coverage versus number of 
clusters assuming a true net benefit of £1000 at £20,000 per QALY cost-effectiveness 
threshold. PQL refers to penalised quasi likelihood, ml refers to maximum likelihood 




Figure 3: Mean bias assume a true net benefit of £1000 at £20,000 per QALY cost-
effectiveness threshold and 95% confidence interval (CI) coverage versus cluster size 
(i.e. number of individuals per cluster). The total number of clusters is fixed at 10. PQL 
refers to penalised quasi likelihood, ml refers to maximum likelihood and reml refers to 




Figure 4: Distribution of total health and social care costs and QALYs accrued over 12 months 
of follow-up in the UK Fashion study displayed by treatment group (HA = Hip Arthroscopy and 




Figure 5: Regression diagnostic plots from fitting Normal errors regression to total NHS/PSS 
costs (4 plots on the top) and QALYs (4 bottom plots) for the UK FASHION study 
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Figure 6: Distribution of costs and QALYs accrued over 28-days displayed by treatment group 
37 
 
Figure 7: Diagnostic plots from fitting normal errors regression to total costs (4 plots on the top) 
and QALYs (4 bottom plots) for the GRACE study 
 
 
